Dextera Biosciences

Dextera Biosciences

Biotechnology, 835 Industrial Rd, San Carlos, California, 94070, United States, 11-50 Employees

dexterabio.com

  • LinkedIn

phone no Phone Number: +16*********

Who is DEXTERA BIOSCIENCES

Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specifi...

Read More

map
  • 835 Industrial Rd, San Carlos, California, 94070, United States Headquarters: 835 Industrial Rd, San Carlos, California, 94070, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $25 Million to $50 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 621511 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from DEXTERA BIOSCIENCES

Dextera Biosciences Org Chart and Mapping

Employees

Andreea Stuparu

Senior Scientist, in Vivo Pharmacology

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Dextera Biosciences

Answer: Dextera Biosciences's headquarters are located at 835 Industrial Rd, San Carlos, California, 94070, United States

Answer: Dextera Biosciences's phone number is +16*********

Answer: Dextera Biosciences's official website is https://dexterabio.com

Answer: Dextera Biosciences's revenue is $25 Million to $50 Million

Answer: Dextera Biosciences's SIC: 2834

Answer: Dextera Biosciences's NAICS: 621511

Answer: Dextera Biosciences has 11-50 employees

Answer: Dextera Biosciences is in Biotechnology

Answer: Dextera Biosciences contact info: Phone number: +16********* Website: https://dexterabio.com

Answer: Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise invisible to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access